Mercado Global de Policitemia Vera – Tendências do setor e previsão para 2029

Análise e dimensão do mercado de pocitomia Vera

Espera-se que o mercado global de pocitomia vera testemunhe um crescimento significativo durante o período de previsão. A policitemia vera é considerada quando o hematócrito atinge mais de 48% nas mulheres e 52% nos homens, enquanto o nível de hemoglobina é superior a 16,5g/Dl nas mulheres e 18,5g/Dl nos homens. O mercado global de tratamento da policitemia está a crescer rapidamente devido ao aumento do número de casos. O tratamento pode incluir flebotomia e terapêutica medicamentosa. O COVID-19 também teve um grande impacto no crescimento do mercado.

A Data Bridge Market Research analisa uma taxa de crescimento no mercado global de pocitomia vera no período de previsão 2022-2029. O CAGR esperado do mercado global de pocitomia vera tende a rondar os 5% no período de previsão mencionado. O mercado foi avaliado em 1.115,9 milhões de dólares em 2021 e cresceria até aos 1.648,69 milhões de dólares até 2029. Para além dos insights sobre cenários de mercado, como o valor de mercado, a taxa de crescimento, a segmentação, a cobertura geográfica e os grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research também incluem análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços e estrutura regulamentar.

Âmbito e segmentação do mercado de Pocitomia Vera

Definição de mercado

A policitemia vera é um tipo raro de cancro do sangue que se inicia na medula óssea. Nesta doença, a medula óssea produz muitos glóbulos vermelhos que podem causar coágulos sanguíneos devido ao espessamento do sangue. A policitemia vera inclui sintomas como dor de cabeça, fraqueza, tonturas, visão dupla, falta de ar e suores geralmente durante a noite. A policitemia vera agrava-se com o tempo se não for diagnosticada e pode ser fatal. Esta condição pode ser tratável, mas não pode ser curada. É de grande importância para o setor da saúde e, por isso, espera-se que aumente muito no período de previsão.

Dinâmica global do mercado de Pocitomia Vera

Motoristas

• Aumento da Policitemia vera

De acordo com o artigo publicado no jornal do Multidisciplinar Digital Publishing Institute (MDPI) em julho de 2020, as taxas de ocorrência anual projetadas para a policitemia vera (PV), trombocitemia essencial (TE) e mielofibrose primária são de 0,84, 1,03 e 0,47 por 100.000 habitantes em todo o mundo e a incidência é muito maior, principalmente para PV e ET, uma vez que as taxas de mortalidade são relativamente baixas em todo o mundo. Isto impulsiona o crescimento do mercado.

• Aprovações mais elevadas de organismos reguladores

Projeta-se que as crescentes aprovações de novos produtos impulsionem o crescimento do mercado durante o período de previsão. Por exemplo, em fevereiro de 2016, a Health Canada aprovou o Jakavi para o controlo do hematócrito em doentes adultos com policitemia vera (PV) resistente ou intolerante a um agente citorredutor. O Jakavi é o primeiro tratamento direcionado aprovado para este tipo de cancro do sangue.

Oportunidades

• Aumento das atividades de I&D

Os principais players que operam no mercado estão a orientar a apresentação de um pedido de aprovação de terapêutica medicamentosa para o tratamento da policitemia vera, o que deverá impulsionar o crescimento do mercado global de terapêutica para a policitemia vera durante o período de previsão. Por exemplo, em maio de 2021, a PharmaEssentia USA Corporation anunciou o reenvio do seu pedido de licença biológica (BLA) para a FDA dos EUA, procurando a aprovação do ropeginterferon alfa-2b-njft para o tratamento da policitemia vera (PV). A nova submissão segue-se à receção de uma carta de resposta completa em março de 2021, na qual a FDA dos EUA procurava informações adicionais sobre o formato de administração do produto. Isto cria mais oportunidades para o crescimento do mercado.

• Maior Indulgência com a Imunoterapia

The segment of immunotherapy is projected to gain further attraction during the forecast period. Immunotherapeutics tend to have less adverse effects when compared to chemotherapeutics. Non-specificity, toxic side effects, and development of resistance associated with chemotherapy are most likely to suppress the growth of chemotherapeutics and boost the adoption of immunotherapeutics and other targeted treatments. This creates more opportunity in the market.

Restraints/Challenges

• Lack of Skilled Professionals

Lack of trained professionals who are not aware of the appropriate treatment methods for this disease could restrain the growth of the global polycytomia vera market over a forecast period.

• Extremely High Cost of Drugs

The huge expenditure of the treatment methods such as immunotherapy, chemotherapy, medications are surely hamper the market growth.

This global polycytomia vera market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global polycytomia vera market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Polycytomia Vera Market

During this Covid-19 pandemic, pharmaceutical business, clinical tool companies and biotechnology firms are facing complications that are happening from the interruption in supply chains and the demand to transform service processes. Suppose Covid-19 pandemic continues for a medium/long duration. In that case, it may effect the supply of product and also active ingredients around the world along with the import as well as export of drugs. There has been a disruption in the treatment market. As coronavirus has actually ended up being the major importance on polycythemia vera therapeutics and all study institutes, biotech as well as pharmaceutical companies are selected in cooperation job to manage Covid-19, who are previously engaged in R&D of therapeutics for the treatment of polycythemia vera.

Global Polycytomia Vera Market Scope

The global polycytomia vera market is segmented on the basis of drug class, treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Antimetabolite
• 6-mercaptopurine
• Fludarabine
• 5-fluorouracil
• Kinase Inhibitors
• Bosutinib
• Crizotinib
• Dasatinib
• Alpha Interferon
• Antivirus Agent
• Protein
• Ribavirin
• Selective Serotonin Reuptake Inhibitors
• Citalopram
• Dapoxetine (Priligy)
• Escitalopram
• Others

Treatment Type

• Myelosuppressive Drugs
• Chemotherapy
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Polycytomia Vera Market Regional Analysis/Insights

The global polycytomia vera market is analysed and market size insights and trends are provided by drug class, treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global polycytomia vera market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the increased incidence of polycytomia vera, high demand of targeted therapies and advanced healthcare facilities.

Asia-Pacific dominates the market due to the increased awareness about diseases and rapidly disposable income.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Polycytomia Vera Market Share Analysis

The global polycytomia vera market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global polycytomia vera market.

Key players operating in the global polycytomia vera market include:

• Cipla Inc. (U.S.)
• Abbott (U.S.)
• AbbVie Inc. (U.S.)
• Merck KGaA (Germany)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Hikma Pharmaceuticals PLC (U.K.)
• Amneal Pharmaceuticals LLC. (U.S.)
• Pfizer Inc (U.S.)
• Mylan N.V. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• GSK plc. (U.K.)
• Bayer AG (Germany)
• Otsuka America Pharmaceutical, Inc (Japão)
• Teva Pharmaceutical Industries Ltd (Israel)
• Gilead Sciences, Inc (EUA)

SKU-54323